Company / Capital Expenditures
Boston Scientific Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$876.0M
FY2025
5-year range
$461.0M / $876.0M
FY2021-FY2025
Trend
+10.9%
vs FY2024
Sector context
#11 of 151
Health Care
What the data says
Among 151 Health Care companies, Boston Scientific is in the top 7% for capital expenditures. Capital Expenditures has increased for 5 consecutive years, from $316M in FY2020 to $876M in FY2025.
Based on SEC 10-K filings.
$876M in FY2025 with a 5-year CAGR of +22.6%. Top quartile in the Health Care sector.
Improved from $711M to $876M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +14.2%
- 5-Year CAGR
- +22.6%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 151This company $876.0M Sector average $271.7M
▼
+222.5% above sector average
Key checks
Key Insights
- Boston Scientific's capital expenditures has grown for 5 consecutive years.
- 5-year CAGR of +22.6%, indicating consistent growth.
- In FY2025, capital expenditures increased 10.9% year-over-year.
- Ranks #11 out of 151 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $876.0M | +10.9% |
| FY2024 | $790.0M | +11.1% |
| FY2023 | $711.0M | +20.9% |
| FY2022 | $588.0M | +27.5% |
| FY2021 | $461.0M | +45.9% |
| FY2020 | $316.0M | -31.5% |
| FY2019 | $461.0M | +45.9% |
| FY2018 | $316.0M | -0.9% |
| FY2017 | $319.0M | -15.2% |
| FY2016 | $376.0M | +52.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026